The non-alcoholic steatohepatitis (NASH) drug market is at the epicenter of a critical healthcare challenge, addressing a rapidly growing liver disease epidemic fueled by the global rise in obesity and metabolic syndrome. The non-alcoholic steatohepatitis drug market is experiencing significant growth, driven by the increasing prevalence of NASH, a severe form of non-alcoholic fatty liver disease (NAFLD) that can lead to cirrhosis and liver failure. Valued at USD 3.1 billion in 2025, the market is projected to reach USD 10 billion by 2035, at a robust CAGR of 12.6%. This growth reflects the urgent unmet need for effective pharmaceutical interventions in this space.

NASH is characterized by fat accumulation in the liver, inflammation, and hepatocellular injury, often progressing to fibrosis. The market is segmented by drug type, with antioxidants and antifibrotic agents being key areas of focus. Antioxidants aim to reduce oxidative stress, a major driver of liver injury, while antifibrotic agents target the scarring process. The market includes various routes of administration, with oral drugs being the most common and preferred for patient convenience. The primary end-users are hospitals and specialty clinics, where patients receive diagnosis and ongoing management.

Key drivers of this market include the increasing prevalence of non-alcoholic fatty liver disease and advancements in research and development. Growing awareness of NASH is also a major factor. For a comprehensive understanding of these dynamics, exploring the non-alcoholic steatohepatitis drug market provides essential insights.